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ear Editor,
In their  case—control  study,  Cherian  et  al.  con-
lude that  ‘‘among  the  residents  of  Kerala,  most
pilepsy  is  not  related  to  cysticercosis,  unlike
ther states  of  India  [1].’’  This  study  highlights
he important  limitations  of  using  seropositivity  for
aenia solium  when  evaluating  the  causal  relation-
hip between  neurocysticercosis  (NC)  and  active
pilepsy  (AE).
In this  study,  none  of  the  patients  with  AE  and
vailable imaging  had  radiographic  evidence  of  NC.
ne-third of  these  patients  had  abnormalities  on
maging that  could  be  considered  causes  of  AE
n their  own,  such  as  mesial  temporal  sclerosis.
nzyme-linked  immunoelectrotransfer  blot  (EITB)
as positive  for  T.  solium  antibodies  in  15%  of
atients  with  AE  and  10.3%  of  controls  (not  statisti-
ally signiﬁcant),  which  is  comparable  to  a  recent
tudy  from  Cameroon  that  also  found  that  seropos-
tivity  is  not  differential  based  on  epilepsy  status
2].  The  present  study  conﬁrms  that  seropositivity
s sometimes  coincidental  in  patients  with  AE,  as
atients who  are  seropositive  and  have  AE  may  lack
ny radiographic  evidence  of  NC.  Nevertheless,  it
lso demonstrates  that  T.  solium  remains  endemic
n Kerala,  as  shown  by  the  existence  of  seropositive
atients who  we  can  assume  had  previous  exposure
o T.  solium  and  presumably  carry  at  least  some,
lbeit unknown  risk  of  developing  NC.  Therefore,
C should  remain  in  the  differential  diagnosis  for
atients with  new-onset  seizures,  hydrocephalus,
r other  neurologic  symptoms  characteristic  of  NC.
Although  the  presence  of  antibodies  against  T.
olium  has  been  associated  with  increased  odds  of
C
N
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C are  not  always  seropositive  [4,5].  This  ﬁnding
ay be  related  to  disease  heterogeneity,  including
yst stage  and  burden,  as  patients  with  calciﬁed
ysts [5]  or  single  lesions  [6]  may  be  less  likely
o be  seropositive.  Furthermore,  not  all  patients
ith NC  develop  epilepsy  and  thus,  seropositivity
n the  absence  of  imaging  cannot  be  expected  to
ccurately  detect  cases  of  AE  related  to  T.  solium
xposure. T.  solium  antigens  are  also  detectable
y EITB  and  enzyme-linked  immunosorbent  assay
ELISA); however,  the  association  between  AE  and
resence  of  T.  solium  antigens  is  also  incon-
istent [7,8],  and  as  with  antibodies,  imaging
ndings suggestive  of  NC  are  not  always  present  in
atients with  AE  who  are  seropositive  for  T.  solium
ntigens  [7].
Although  NC  can  lead  to  epilepsy  (i.e.,  recurrent,
nprovoked seizures)  in  some  patients,  studies  that
ely on  detecting  T.  solium  antibodies  or  antigens
s a surrogate  for  actual  clinical  diagnosis  of  NC
istort this  relationship  [9].  Determining  seroposi-
ivity  to  T.  solium  is  useful  in  identifying  endemic
egions, but  it  may  also  be  useful  in  diagnos-
ng NC  in  combination  with  imaging  studies  and
linical  history  and  evaluation.  Diagnosis  of NC
emains  a challenge,  as  consensus  diagnostic  crite-
ia for  NC  exist  [10], but  have  not  been  formally
alidated and  may  have  limited  applicability  for
xtraparenchymal  disease.  As  NC  is  one  of  the  many
ossible causes  of  epilepsy,  long-term  prospective
ohort studies  are  needed  to  better  determine
he pathogenesis  and  epidemiology  of  NC-related
pilepsy.
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